Neuronano AB

Our Professor Jens Schouenborg was invited to participate as a speaker at Smer’s symposium “Bioethics in a Time of Global Crises and Scientific Breakthroughs” in Stockholm earlier this October, where he presented on emerging neurotechnologies for treatment-resistant brain disorders. Together with a number of international experts, the event offered a rich program of lectures, panel discussions, and Q&A sessions—focusing on bioethics at the intersection of global crises and rapid scientific advances.

Explore the full programme here for all the topics and speakers that were discussed.: https://smer.se/bioethics-in-a-time-of-global-crises-and-scientific-breakthroughs-3/

Neuronano is excited to share that our new colleague Hari Subramanian will attend the 26th Congress of the European Society for Stereotactic and Functional Neurosurgery (ESSFN) at the Budapest Congress Center, 24–27 September 2025.

We’re looking forward to connecting with clinicians, researchers, and industry leaders across stereotactic and functional neurosurgery, including neuromodulation and DBS.

On May 27 we had the pleasure of having SMER as guest at Neuronano Research and Innovation Center. After introductions and summary presentation of our work by Prof. Jens Schouenborg, there where interesing discussion followed by a brief visit to our laboratory facility.

At Neuronano, our experienced histologists, Dr Lina Pettersson and Dr Lina Gällentoft, are driving research in neurotechnology forward. Their work focuses on studies of how the brain responds to advanced implants, helping to optimize materials and methodologies to minimize inflammation while maximizing implant functionality.

Their expertise enables the development of next-generation brain implants to treat Parkinson’s disease and other neurological disorders. Their research enhances our understanding of how brain tissue responds and paves the way for the future of precision medicine and personalized treatments.

Histologists' work has been fundamental to many medical breakthroughs, and at Neuronano, they are actively shaping the future of neuroscience.

On May 8, we’re participating in Neuroscience Day – an inspiring event where researchers exploring the mysteries of the brain come together to share new ideas! 💡

Organized by Lund University and the Faculty of Medicine, and supported by the Segerfalk Foundation, the day brings together both experienced and early-career researchers with a shared goal: to understand and improve the lives of those affected by neurological diseases.

A highlight this year? ✨ The keynote lecture by Dr. Andres Lozano from Toronto – a world-renowned neurosurgeon and pioneer in deep brain stimulation (DBS), used to treat conditions such as Parkinson’s, depression, and Alzheimer’s.

🔗 Read more about Neuroscience Day here: https://ow.ly/fbMf50VOj5Q

Brain implant technology is advancing at an unprecedented pace, opening up a world of possibilities. But what can next-generation implants truly offer? Here are some potential applications:

For individuals living with Parkinson’s disease, advanced neurotechnology presents a future with groundbreaking treatment possibilities. But what does "virtually unlimited therapeutic potential" truly mean?

🔹 Precision Treatment – Emerging brain implants and neurostimulation technologies can tailor therapies in real-time, effectively reducing symptoms such as tremors and stiffness.

🔹 Extended Disease Management – Modern therapies have the potential to slow disease progression and enhance quality of life over a longer period.

🔹 Personalized Medicine – Neurotechnology enable customized treatment solutions that optimize care for each individual patient.

🔹 Reduced Side Effects – With more precise and adaptive therapies, patients may rely less on medication, thereby avoiding many of the side effects associated with traditional drugs.

Technological advancements are paving the way for a future where Parkinson’s disease becomes increasingly manageable. The question is no longer if but when we will see a revolution in neurological care.

We are proud to announce that Dr Hari Subramanian, former Chief Scientist & Senior Fellow for the neuromodulation division, comprising DBS and pain franchises at Boston Scientific Inc, has been employed as Vice President for Business Development, Medical & Scientific Affairs in Neuronano AB’s US-based subsidiary. We are thrilled to have Dr Subramanian on board and look forward to this new phase in Neuronano AB.

Vi är stolta över att meddela att Dr Hari Subramanian, tidigare Chief Scientist & Senior Fellow för neuromoduleringsdivisionen, som omfattar DBS och smärtfranchiser på Boston Scientific Inc, har anställts som vice president för affärsutveckling, medicinska och vetenskapliga angelägenheter i Neuronano AB:s USA-baserade dotterbolag. Vi är glada över att ha Dr Subramanian ombord och ser fram emot denna nya fas i Neuronano AB.

It is no coincidence that our research and development is based in Medicon Village, Lund. Together with 180 other companies, Medicon Village forms the largest science park in Scandinavia, focused on Life Science.
Medicon Village is part of Medicon Valley, one of Europe’s top Life Science clusters, linking southern Sweden and eastern Denmark. The region combines Sweden’s strength in medtech with Denmark’s pharmaceutical expertise, offering easy access to international markets. With 12 universities and world-class research institutes, Medicon Valley provides a vibrant innovative atmosphere with unique business opportunities to leverage advanced research and skilled talent.

Conventional technology in Deep Brain Stimulation (DBS) utilizes leads with an approximate diameter of 1.3 mm. This is 10-100 times the size of a typical brain cell, affecting a significant amount of tissue during implantation. Neuronano’s solution is to use microelectrodes, with a similar diameter as the typical neuron, which enables a smooth implantation with minimal damage to the tissue to be stimulated.

How do we get adequate stimulation at the correct spot, you may ask?

By using a cluster of microelectrodes spread in the target area, we can select the microelectrode(s) closest to the optimal position for maximal symptom relief.

Read more about our ongoing research at neuronano.se
“The future is near."